Drug Type Oligonucleotide |
Synonyms- |
Target |
Action inhibitors |
Mechanism LRRK2 inhibitors(Leucine-rich repeat serine/threonine-protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Parkinson Disease | Discovery | United States | 22 Mar 2024 |





